CS5001 (ROR1 ADC) Kev Tshawb Fawb Cov Ntaub Ntawv Los ntawm Cstone Pharmaceuticals tau raug xaiv rau hauv 33rd International Conference Ntawm Molecular Targets Thiab Cancer Therapy hauv 2021, Blockbuster Research Abstract (LBA)

Thaum lub Cuaj Hlis 28, Hong Kong cov ntawv teev npe tshiab lub tuam txhab tshuaj Cstone Pharmaceuticals (HK, 2616) tshaj tawm tias nws lub peev xwm thoob ntiaj teb cov tshuaj zoo tshaj plaws hauv chav kawm CS5001 (ROR1 ADC) hais txog cov tshuaj tshuaj thiab tshuaj pharmacodynamics preclinical tshawb fawb cov ntaub ntawv raug xaiv raws li 33rd hauv 2021 AACR-NCI-EORTC Lub Rooj Sib Tham Thoob Ntiaj Teb ntawm Molecular Targets thiab Cancer Therapeutics (late-breaking abstract, LBA) yuav raug nthuav tawm hauv daim ntawv tshaj tawm virtual. Cov txiaj ntsig tau pom tias CS5001 yog tus neeg sib tw tshuaj muaj txiaj ntsig nrog kev kho mob muaj peev xwm hauv cov qog ntshav hematological thiab cov qog nqaij hlav malignant nrog siab ROR1 qhia.

• Kev tshawb fawb teb: ntau yam ntawm cov qog nqaij hlav thiab cov qog hematological

• Hnub tim: Lub Kaum Hli 7-10, 2021

•Txhais hom ntawv: Late-breaking abstract (LBA)

• Title: CS5001 yog ib yam tshuaj tshiab los tiv thaiv kab mob sib kis (ADC) lub hom phiaj ROR1 nrog cov qog tshwj xeeb ua kom muaj pyrrolobenzodiazepine (PBD) protoxin, uas yuav tsum tau siv rau hauv kev kho cov qog hematological thiab Malignant khoom qog.

• Tus Thawj Coj/Tus Thawj Saib Xyuas Kev Tshawb Fawb: Dr. Xie Yizhao, Tus Thawj Saib Xyuas Kev Tshawb Fawb ntawm Cstone Pharmaceuticals

Qhov no yog zaum thib peb Cstone Pharmaceuticals yuav nthuav tawm qhov kev tshawb fawb tshiab tshaj plaws rau cov kws tshawb fawb thoob ntiaj teb ntawm World Cancer Diagnosis and Treatment Summit tom qab World Lung Cancer Congress thiab European Society of Medical Oncology Lub Rooj Sib Tham Txhua Xyoo hauv ib hlis, thiab cov haujlwm hauv txhua peb. Cov rooj sib tham tau raug xaiv rau LBA. Nws cim tias Cstone' qhov kev tsim kho tshuaj tshiab muaj peev xwm tau lees paub los ntawm kev lag luam thoob ntiaj teb.

Nws tau nkag siab tias CS5001 yog ib qho tshuaj tiv thaiv kab mob preclinical-conjugated (ADC) lub hom phiaj receptor tyrosine kinase-zoo li menyuam ntsuag receptor 1, ROR1, thiab tam sim no tab tom ua kev sim tshuaj tshiab ntawm cov tshuaj thov rau kev tshawb fawb. ROR1 yog lub hom phiaj ADC uas muaj peev xwm ua tau ntau yam ntawm cov khoom thiab hematological malignancies, nrog rau ntau hom leukemia, non-Hodgkin's lymphoma, mob cancer mis, mob ntsws cancer thiab zes qe menyuam.

CS5001 muaj cov qauv tsim tshwj xeeb, siv cov qog tshwj xeeb qhib pyrrolobenzodiazepine (PBD) protoxin payload (Payload) thiab txuas (linker). Tsuas yog tom qab CS5001 ncav cuag cov qog, nws cov linker yog cleaved los tso PBD protoxin, thiab tom qab ntawd PBD protoxin tau qhib rau hauv cov qog hlwb, yog li tua cov qog hlwb. Qhov no" dual tswj" mechanism ntawm linker plus protoxin zoo daws cov teeb meem toxicity raug cuam tshuam nrog cov tsoos PBD loads thiab muaj lub qhov rais loj dua kev nyab xeeb. CS5001 tau raug pov thawj tias muaj cov qog ua kom tiav cov teebmeem hauv ntau cov qauv mob qog noj ntshav, thiab nthuav tawm cov ntshav zoo ib nrab-lub neej thiab cov tshuaj pharmacokinetic. Cov no yuav raug hloov mus rau hauv ntau yam kev ntsuas kev kho mob rau ntau yam khoom thiab hematological malignancies. Tsis tas li ntawd, CS5001 siv cov thev naus laus zis sib txuas ua ke kom tau txais cov tshuaj-rau-antibody piv (DAR), uas pab txhawb kev ua tiav ntawm homogeneous ntau lawm thiab cov khoom loj.

Thaum Lub Kaum Hli 2020, Cstone Pharmaceuticals thiab LegoChem Biosciences, Inc. (" LCB") tau mus txog daim ntawv tso cai pom zoo rau kev txhim kho thiab kev lag luam ntawm CS5001. Raws li cov ntsiab lus ntawm daim ntawv cog lus, Cstone Pharmaceuticals tau txais daim ntawv tso cai tshwj xeeb los coj txoj kev loj hlob thiab kev lag luam ntawm CS5001 hauv lwm thaj tsam ntawm lub ntiaj teb sab nraud Kauslim. Kev tshawb fawb tau ua tiav los ntawm Cstone Pharmaceuticals, LCB Company, thiab South Kauslim' s ABL Bio Company.